The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis
Abstract
BACKGROUND: Patients with bronchiectasis have frequent exacerbations that are thought to be related to neutrophilic inflammation. The activity and quantity of neutrophil serine proteases, including neutrophil elastase, are increased in the sputum of patients with bronchiectasis at baseline and increase further during exacerbations. Brensocatib (INS1007) is an oral reversible inhibitor of dipeptidyl peptidase 1 (DPP-1), an enzyme responsible for the activation of neutrophil serine proteases. METHODS: In a phase 2, randomized, double-blind, placebo-controlled trial, we randomly assigned, in a 1:1:1 ratio, patients with bronchiectasis who had had at least two exacerbations in the previous year to receive placebo, 10 mg of brensocatib, or 25 mg of brensocatib once daily for 24 weeks. The time to the first exacerbation (primary end point), the rate of exacerbations (secondary end point), sputum neutrophil elastase activity, and safety were assessed. RESULTS: Of 256 patients, 87 were assigned to receive placebo, 82 to receive 10 mg of brensocatib, and 87 to receive 25 mg of brensocatib. The 25th percentile of the time to the first exacerbation was 67 days in the placebo group, 134 days in the 10-mg brensocatib group, and 96 days in the 25-mg brensocatib group. Brensocatib treatment prolonged the time to the first exacerbation as compared with placebo (P = 0.03 for 10-mg brensocatib vs. placebo; P = 0.04 for 25-mg brensocatib vs. placebo). The adjusted hazard ratio for exacerbation in the comparison of brensocatib with placebo was 0.58 (95% confidence interval [CI], 0.35 to 0.95) in the 10-mg group (P = 0.03) and 0.62 (95% CI, 0.38 to 0.99) in the 25-mg group (P = 0.046). The incidence-rate ratio was 0.64 (95% CI, 0.42 to 0.98) in the 10-mg group, as compared with placebo (P = 0.04), and 0.75 (95% CI, 0.50 to 1.13) in the 25-mg group, as compared with placebo (P = 0.17). With both brensocatib doses, sputum neutrophil elastase activity was reduced from baseline over the 24-week treatment period. The incidence of dental and skin adverse events of special interest was higher with the 10-mg and 25-mg brensocatib doses, respectively, than with placebo. CONCLUSIONS: In this 24-week trial, reduction of neutrophil serine protease activity with brensocatib in patients with bronchiectasis was associated with improvements in bronchiectasis clinical outcomes. (Funded by Insmed; WILLOW ClinicalTrials.gov number, NCT03218917.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
The bronchiectasis severity index. An international derivation and validation study
Chalmers, J. D., Goeminne, P., Aliberti, S., McDonnell, M. J., Lonni, S., Davidson, J., Poppelwell, L., Salih, W., Pesci, A., Dupont, L. J., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201309-1575oc · Cited by 1,093
Self-citationBarker, A. F. (2002) · New England Journal of Medicine · doi:10.1056/nejmra012519 · Cited by 551
Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research
Hill, A. T., Haworth, C. S., Aliberti, S., Barker, A., Blasi, F., Boersma, W., Chalmers, J. D., De Soyza, A., Dimakou, K., Elborn, J. S., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.00051-2017 · Cited by 439
Self-citationChalmers, J. D., Moffitt, K. L., Suarez-Cuartin, G., Sibila, O., Finch, S., Furrie, E., Dicker, A., Wrobel, K., Elborn, J. S., Walker, B., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201605-1027oc · Cited by 416
Self-citationValidation of the St. George's Respiratory Questionnaire in Bronchiectasis
WILSON, C. B., JONES, P. W., O'LEARY, C. J., COLE, P. J., & WILSON, R. (1997) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.156.2.9607083 · Cited by 387
Vandivier, R. W., Fadok, V. A., Hoffmann, P. R., Bratton, D. L., Penvari, C., Brown, K. K., Brain, J. D., Accurso, F. J., & Henson, P. M. (2002) · Journal of Clinical Investigation · doi:10.1172/jci13572 · Cited by 373
Characterization of the “Frequent Exacerbator Phenotype” in Bronchiectasis
Chalmers, J. D., Aliberti, S., Filonenko, A., Shteinberg, M., Goeminne, P. C., Hill, A. T., Fardon, T. C., Obradovic, D., Gerlinger, C., Sotgiu, G., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201711-2202oc · Cited by 351
Self-citationVandivier, R. W., Fadok, V. A., Hoffmann, P. R., Bratton, D. L., Penvari, C., Brown, K. K., Brain, J. D., Accurso, F. J., & Henson, P. M. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0213572 · Cited by 327
ICH harmonized tripartite guideline: Guideline for Good Clinical Practice.
(2001) · PubMed · Cited by 243
Quittner, A. L., O'Donnell, A. E., Salathe, M. A., Lewis, S. A., Li, X., Montgomery, A. B., O'Riordan, T. G., & Barker, A. F. (2015) · Thorax · doi:10.1136/thoraxjnl-2014-205918 · Cited by 219
Self-citationBronchiectasis: new therapies and new perspectives
Chalmers, J. D., & Chotirmall, S. H. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30053-5 · Cited by 211
Self-citationMechanisms of immune dysfunction and bacterial persistence in non-cystic fibrosis bronchiectasis
Chalmers, J. D., & Hill, A. T. (2013) · Molecular Immunology · doi:10.1016/j.molimm.2012.09.011 · Cited by 200
Self-citationDe Soyza, A., Aksamit, T., Bandel, T.-J., Criollo, M., Elborn, J. S., Operschall, E., Polverino, E., Roth, K., Winthrop, K. L., & Wilson, R. (2018) · European Respiratory Journal · doi:10.1183/13993003.02052-2017 · Cited by 188
Aksamit, T., De Soyza, A., Bandel, T.-J., Criollo, M., Elborn, J. S., Operschall, E., Polverino, E., Roth, K., Winthrop, K. L., & Wilson, R. (2018) · European Respiratory Journal · doi:10.1183/13993003.02053-2017 · Cited by 188
Validation of the Leicester Cough Questionnaire in non-cystic fibrosis bronchiectasis
Murray, M. P., Turnbull, K., MacQuarrie, S., Pentland, J. L., & Hill, A. T. (2009) · European Respiratory Journal · doi:10.1183/09031936.00160508 · Cited by 169
Papillon-Lefèvre syndrome patient reveals species-dependent requirements for neutrophil defenses
Sørensen, O. E., Clemmensen, S. N., Dahl, S. L., Østergaard, O., Heegaard, N. H., Glenthøj, A., Nielsen, F. C., & Borregaard, N. (2014) · Journal of Clinical Investigation · doi:10.1172/jci76009 · Cited by 167
Assessment of airway neutrophils by sputum colour: correlation with airways inflammation
Stockley, R. A., Bayley, D. L., Hill, S. L., Hill, A. T., Crooks, S., & Campbell, E. J. (2001) · Thorax · doi:10.1136/thorax.56.5.366 · Cited by 166
Konstan, M. W., Döring, G., Heltshe, S. L., Lands, L. C., Hilliard, K. A., Koker, P., Bhattacharya, S., Staab, A., & Hamilton, A. (2014) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2013.12.009 · Cited by 140
Sputum colour: a useful clinical tool in non-cystic fibrosis bronchiectasis
Murray, M., Pentland, J. L., Turnbull, K., MacQuarrie, S., & Hill, A. T. (2009) · European Respiratory Journal · doi:10.1183/09031936.00163208 · Cited by 137
A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis
Soyza, A. D., Pavord, I. D., Elborn, J. S., Smith, D., Wray, H., Puu, M., LARSSON, B. S., & Stockley, R. A. (2015) · European Respiratory Journal · doi:10.1183/13993003.00148-2015 · Cited by 114
Dubois, A. V., Gauthier, A., Bréa, D., Varaigne, F., Diot, P., Gauthier, F., & Attucci, S. (2012) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2011-0380oc · Cited by 109
Palmér, R., Mäenpää, J., Jauhiainen, A., LARSSON, B. S., Mo, J., Russell, M., Root, J. A., Prothon, S., Chialda, L., Forte, P., et al. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1053 · Cited by 109
Shoemark, A., Cant, E., Carreto, L., Smith, A., Oriano, M., Keir, H. R., Perea, L., Cantó, E., Terranova, L., Vidal, S., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.00303-2019 · Cited by 100
Self-citationAntimicrobial peptides, disease severity and exacerbations in bronchiectasis
Sibila, O., Perea, L., Cantó, E., Shoemark, A., Cassidy, D. M., Smith, A., Suárez-Cuartín, G., Rodrigo‐Troyano, A., Keir, H. R., Oriano, M., et al. (2019) · Thorax · doi:10.1136/thoraxjnl-2018-212895 · Cited by 73
Self-citationGoeminne, P., Vandooren, J., Moelants, E. A. V., Decraene, A., Rabaey, E., Pauwels, A., Seys, S., Opdenakker, G., Proost, P., & Dupont, L. (2013) · Respirology · doi:10.1111/resp.12219 · Cited by 69
Cited by
Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission
Stolz, D., Mkorombindo, T., Schumann, D. M., Agusti, A., Ash, S. Y., Bafadhel, M., Bai, C., Chalmers, J. D., Criner, G. J., Dharmage, S. C., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01273-9 · Cited by 681
Self-citation
Metadata
- Authors
- Chalmers, J. D., Haworth, C. S., Metersky, M. L., Loebinger, M. R., Blasi, F., Sibila, O., O’Donnell, A. E., Sullivan, E. J., Mange, K. C., Fernandez, C., Zou, J., & Daley, C. L.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-11-26
- Volume
- 383
- Issue
- 22
- Pages
- 2127-2137
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3083763949
- Cited by
- 377
- References
- 27
- FWCI
- 20.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.